Sarah Alane Andres

US Patent:

20110165566, Jul 7, 2011

Filed:

Jul 8, 2010

Appl. No.:

12/832474

Inventors:

James L. Wittliff - Louisville KY, US
Sarah A. Andres - Floyds Knobs IN, US

International Classification:

C12Q 1/68

US Classification:

435 611

Abstract:

Breast cancer treatment can be optimized by determining the level of expression of genes in a breast sample from a human to identify a human with an increased likelihood of recurrence of the breast cancer that would potentially benefit from a therapy to decrease the likelihood of recurrence of the breast cancer.

US Patent:

20110065115, Mar 17, 2011

Filed:

Sep 20, 2010

Appl. No.:

12/885720

Inventors:

James L. Wittliff - Louisville KY, US
Sarah A. Andres - Floyds Knobs IN, US

Assignee:

University of Louisville Research Foundation, Inc. - Louisville KY

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

Methods of identifying a mammal having an increased likelihood of recurrence of breast cancer includes identifying in a breast tissue sample of the mammal expression of at least two genes selected from the group consisting of Hs.125867 (EVL), Hs.591847 (NAT1), Hs.208124 (ESR1), Hs.26225 (GABRP), Hs.408614 (ST8SIA1), Hs.480819 (TBC1D9), Hs.504115 (TRIM29), Hs.523468 (SCUBE2), Hs.532082 (IL6ST), Hs.592121 (RABEP1), Hs.79136 (SLC39A6), Hs.82128 (TPBG), Hs.95243 (TCEAL1), Hs.95612 (DSC2), Hs.654961 (FUT8), Hs.1594 (CENPA), Hs.184339 (MELK), Hs.26010 (PFKP), Hs.592049 (PLK1), Hs.370834 (ATAD2), Hs.437638 (XBP1), Hs.444118 (MCM6), Hs.469649 (BUB1), Hs.470477 (PTP4A2), Hs.473583 (YBX1), Hs.480938 (LRBA), Hs.524134 (GATA3), Hs.531668 (CX3CL1), Hs.532824 (MAPRE2), Hs.591314 (GMPS), Hs.83758 (CKS2) and Hs.99962 (SLC43A3) and subsets of the genes.

US Patent:

20200108050, Apr 9, 2020

Filed:

Oct 9, 2019

Appl. No.:

16/597027

Inventors:

- Louisville KY, US
Sarah A. ANDRES - Floyds Knobs IN, US
Joseph A. BURLISON - Louisville KY, US

Assignee:

UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. - Louisville KY

International Classification:

A61K 31/4188
A61K 31/045
A61K 31/08
A61K 31/035
A61K 31/121
A61K 31/133
A61K 31/085
A61K 31/095
A61K 31/22
A61K 31/351

Abstract:

Some embodiments of the invention include methods of using a compound such as Formula (I), Formula (II), or I-1 (e.g., in compositions or in pharmaceutical compositions) for treating diseases (e.g., cancer such as chemo-resistant cancer or cancer-therapy-resistant cancer). Additional embodiments of the invention are also discussed herein.

US Patent:

20200062703, Feb 27, 2020

Filed:

Nov 3, 2019

Appl. No.:

16/672481

Inventors:

- Louisville KY, US
Robert M. Buchanan - Louisville KY, US
Nicholas S. Vishnosky - Marlborough CT, US
Jason O. E. Young - Owensboro KY, US
Paula J. Bates - Louisville KY, US
Sarah A. Andres - Floyds Knobs IN, US
Caleb Aaron Calvary - Louisville KY, US

Assignee:

UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. - Louisville KY

International Classification:

C07C 335/40
C07D 265/30
A61P 35/00

Abstract:

Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I) or (Ia)). Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as cancer). Further embodiments include methods for making the inventive compounds. Additional embodiments of the invention are also discussed herein.

US Patent:

20100112592, May 6, 2010

Filed:

Dec 3, 2009

Appl. No.:

12/630212

Inventors:

James L. Wittliff - Louisville KY, US
Sarah A. Andres - Floyds Knobs IN, US

Assignee:

UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. - LOUISVILLE KY

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

Methods of identifying a mammal having an increased likelihood of recurrence of breast cancer includes identifying in a breast tissue sample of the mammal expression of at least two genes selected from the group consisting of Hs.125867 (EVL), Hs.591847 (NAT1), Hs.208124 (ESR1), Hs.26225 (GABRP), Hs.408614 (ST8SIA1), Hs.480819 (TBC1D9), Hs.504115 (TRIM29), Hs.523468 (SCUBE2), Hs.532082 (IL6ST), Hs.592121 (RABEP1), Hs.79136 (SLC39A6), Hs.82128 (TPBG), Hs.95243 (TCEAL1), Hs.95612 (DSC2), Hs.654961 (FUT8), Hs.1594 (CENPA), Hs.184339 (MELK), Hs.26010 (PFKP), Hs.592049 (PLK1), Hs.370834 (ATAD2), Hs.437638 (XBP1), Hs.444118 (MCM6), Hs.469649 (BUB1), Hs.470477 (PTP4A2), Hs.473583 (YBX1), Hs.480938 (LRBA), Hs.524134 (GATA3), Hs.531668 (CX3CL1), Hs.532824 (MAPRE2), Hs.591314 (GMPS), Hs.83758 (CKS2) and Hs.99962 (SLC43A3) and subsets of the genes.